CD19 and B-cell acute lymphoblastic leukemia: Although complete remission has been achieved in 60–90% of patients with B cell acute lymphoblastic leukemia (15–17), CD19.CAR-T cells are less effective for diffuse large B-cell lymphoma (40–50%) (17, 18) and CLL (15–30%) (19, 20).